Real-world Canadian Retrospective Study Evaluating Longitudinal Semaglutide Use on Cardio-Kidney-Metabolic Outcomes
Starting soon
Conditions studied: Diabetes (DM), Type 2 Diabetes, Obesity (Disorder)
In brief
The goal of this study is to better understand the real-world effectiveness of semaglutide use on cardio-kidney-metabolic outcomes among adults with T2D and adults with obesity (without diabetes mellitus). This is a retrospective longitudinal analysis using the LMC Diabetes Registry. The primary outcome of the study is to evaluate the change in HbA1c between baseline to 3 years of follow-up among adults with T2D who initiated semaglutide compared to adults with T2D who initiated other AHAs, including sulfonylurea, dipeptidyl peptidase-4 inhibitors, and sodium-glucose cotransporter-2 inhibitors.
Key facts
- Study ID
- NCT07424430
- Run by
- LMC Diabetes & Endocrinology Ltd.
- People needed
- 400
- Starts
- 2026-03-01
- Expected to finish
- 2026-05-01
- Last updated by the study team
- 2026-02-20
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- T2D Cohort:
- A clinical diagnosis of T2D ≥ 1 year
- HbA1c ≥ 6.5% (pre-index date)
- Initiated semaglutide or other AHA(s) before January 1st, 2023*
- Seen by an LMC endocrinologist in the last 18 months as of the query date
- ≥ one HbA1c value up to 6 months (+ 90 days) prior to index date
- Informed data consent for their medical record data to be used for research purposes
- Obesity Cohort:
- 18 years or older
- BMI ≥ 27 kg/m2
- HbA1c < 6.5% (pre-index date)
- Initiated semaglutide before January 1st, 2023*
- Seen by an LMC endocrinologist in the last 18 months as of the query date
- ≥ one HbA1c value up to 6 months (± 90 days) prior to index date
- Informed data consent for their medical record data to be used for research purposes
You may not qualify if…
- Clinical diagnosis of type 1 diabetes/latent autoimmune diabetes in adults (LADA)
- Clinical diagnosis of T2D (obesity cohort only)
- Are pregnant at the time of semaglutide or other AHA initiation or became pregnant during follow-up period
- Documented history or family history of medullary thyroid carcinoma
- Participation in a research study with an Investigational Product
- eGFR < 15 mL/min/1.73m2 at index date
- Use of non-semaglutide GLP-1-based medication for more than 6 months after the index date (T2D sema cohort and obesity sema cohort)
- Use of other AHA for more than 6 months after the index date within the first year of semaglutide use (T2D sema cohort and obesity sema cohort)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.